Discover 1 curated intelligence briefings related to this specific topic.
Clinics are abandoning the costly, slow process of ex-vivo cell manipulation in favor of in-vivo delivery. This shift, powered by new lipid nanoparticles and viral vectors, is moving gene therapy from rare-disease niches into mainstream clinical practice.
